SiBone (NASDAQ:SIBN) Issues Quarterly Earnings Results

Key Points

• SiBone reported a quarterly earnings per share of ($0.14), which exceeded the analysts' consensus estimate of ($0.19) by $0.05.
• The company's stock price increased to $17.90 during trading, and it has a market capitalization of $762.81 million.
• Several hedge funds have recently adjusted their positions, with a significant 98.11% of the stock now owned by institutional investors.

SiBone (NASDAQ:SIBN - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05, Zacks reports. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. SiBone updated its FY 2025 guidance to EPS.

SiBone Price Performance

SiBone stock traded up $0.51 during midday trading on Monday, reaching $17.90. The company's stock had a trading volume of 672,343 shares, compared to its average volume of 419,685. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05. The company has a current ratio of 8.53, a quick ratio of 7.26 and a debt-to-equity ratio of 0.21. The business has a 50-day moving average price of $17.90 and a 200-day moving average price of $16.63. The stock has a market cap of $762.81 million, a PE ratio of -27.97 and a beta of 0.91.

Insider Transactions at SiBone

In other news, Director Jeffrey W. Dunn sold 3,377 shares of the business's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $19.05, for a total transaction of $64,331.85. Following the sale, the director directly owned 17,354 shares in the company, valued at approximately $330,593.70. The trade was a 16.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Laura Francis sold 38,504 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total value of $661,498.72. Following the sale, the chief executive officer owned 302,958 shares in the company, valued at approximately $5,204,818.44. This trade represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 101,366 shares of company stock valued at $1,861,774. Company insiders own 4.00% of the company's stock.

Hedge Funds Weigh In On SiBone

A number of hedge funds and other institutional investors have recently made changes to their positions in SIBN. Jane Street Group LLC acquired a new position in shares of SiBone in the first quarter worth approximately $1,818,000. Goldman Sachs Group Inc. lifted its stake in SiBone by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company's stock valued at $5,328,000 after buying an additional 83,919 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in SiBone in the first quarter valued at approximately $225,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company's stock valued at $343,000 after buying an additional 1,053 shares during the period. 98.11% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have weighed in on SIBN. Truist Financial increased their price objective on SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price target on shares of SiBone in a research note on Tuesday, May 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price target on shares of SiBone in a research note on Tuesday, May 6th.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.